Redenlab

Redenlab Inc is an industry leading neuroscience focussed tech bio. We use speech and language biometrics to improve decision-making in clinical trials. Whether the trials take place in clinic, at home, or virtually, our tests are sensitive and reliable, accurately detecting subtle changes caused by disease or treatment. Our speech software and hardware solutions meet all the regulatory requirements for data security and integrity in clinical trials, including 21 CFR Part 11 and HIPAA. Follow us to find out more about our groundbreaking projects and explore the future of speech analysis at www.redenlab.com

Neuroscience,speech,language,dysphagia,clinical trials,analysis pipeline,biometrics,neurology,acoustics,science,technology,biomarkers,pharmaceuticals,rare disease,dementia,ataxia,parkinson's disease,huntington's disease,motor neurone disease,autism,neurodegeneration,and neurodevelopment

Redenlab operates in the Biotechnology research industry.

Redenlab's revenue is 11m - 100m

Redenlab has 11 - 50 employees.